Abstract:
:Beclin-1 is a key regulator of autophagy and has been suggested to be involved in the development of drug resistance in multiple myeloma (MM). We analyzed the expression of Beclin-1 in a retrospective cohort of 70 MMs. Beclin-1 expression did not influence overall survival (OS) and progression-free survival (PFS) in patients with therapy-naïve MM. In patients treated with immunomodulatory drugs (IMiDs) lack of or low Beclin-1 expression resulted in a significantly improved OS and PFS compared to those treated with bortezomib or nonnovel agents. Beclin-1 expression was more frequently detected in relapsed MM than in therapy-naïve MM probably being a hallmark of tumor progression and therapy resistance. If validated prospectively, Beclin-1 expression might identify patients prone to profit above average from IMiDs and enable a more rational allocation of antimyeloma therapies. Furthermore, the inhibition of autophagy could be a new promising target to improve response to treatment in the relapsed/refractory setting.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Willenbacher W,Thangavadivel S,Greil R,Willenbacher E,Weger R,Manzl C,Jöhrer K,Brunner Adoi
10.3109/10428194.2016.1144880subject
Has Abstractpub_date
2016-10-01 00:00:00pages
2330-41issue
10eissn
1042-8194issn
1029-2403journal_volume
57pub_type
杂志文章abstract::The relation between resistance to anticancer drugs and resistance to apoptosis has been investigated in the human leukemic cell line(KY-821) and its drug-resistant sublines. Under serum depletion conditions, drug-resistant cell lines showed apoptotic resistance when compared with the parental cell line. Drug resistan...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199709051787
更新日期:1997-07-01 00:00:00
abstract::Genistein is one of the major isoflavones in soy products. It has been reported that genistein has apoptotic effects on certain hematological malignancies. However, so far there have been no completely comparative studies of the effect of genistein on malignant hematological diseases, especially multiple myeloma. We i...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2011.598251
更新日期:2011-12-01 00:00:00
abstract::In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study. Patients with AML undergoing induction or postremission consolidati...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3109/10428199509059668
更新日期:1995-09-01 00:00:00
abstract::Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190310001638823
更新日期:2004-06-01 00:00:00
abstract::In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199709042502
更新日期:1997-03-01 00:00:00
abstract::Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190500331329
更新日期:2006-03-01 00:00:00
abstract::We have previously described a relation between abundance of eosinophilic granulocytes in Hodgkin's disease (HD) tumours and poor prognosis. In order to further explore the importance of the eosinophilic infiltration, we immunohistochemically examined the presence of eosinophils, using the monoclonal antibodies EG 1 a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190109064602
更新日期:2001-07-01 00:00:00
abstract::We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2020.1869965
更新日期:2021-01-22 00:00:00
abstract::Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoma that requires treatment. We retrospectively analyzed the impact of time from diagnosis-to-treatment (TDT) on progression-free survival (PFS) and overall survival (OS) in 581 R-CHOP-treated patients. TDT was defined as the interval between diagnostic biopsy...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2017.1422863
更新日期:2018-10-01 00:00:00
abstract::Plasmablastic lymphoma (PBL) is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients. Several studies have reported the occurrence of PBL in HIV-negative patients, but comparative data are lacking. The goal of this study was to compare the characteristics of HIV-positive and...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2010.516040
更新日期:2010-11-01 00:00:00
abstract::Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2018.1510495
更新日期:2019-03-01 00:00:00
abstract::We investigated whether etoposide might be a suitable alternative to anthracyclins for the treatment of elderly patients with acute myeloid leukemia (AML) in whom anthracyclins are contraindicated. In total, 88 patients over 60 years old were treated in our department between 1988 and 2000 for de novo or secondary AML...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190400013134
更新日期:2005-03-01 00:00:00
abstract::The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428190009059268
更新日期:2000-08-01 00:00:00
abstract::The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2014.944521
更新日期:2015-04-01 00:00:00
abstract::The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2010.531410
更新日期:2011-01-01 00:00:00
abstract::The addition of arsenic trioxide (ATO) to frontline therapy of acute promyelocytic leukemia (APL) has been shown to result in significant improvements in disease-free survival (DFS). FLT3 mutations are frequently observed in APL, but its prognostic significance remains unclear. We analyzed 245 newly diagnosed adult pa...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3109/10428194.2013.842985
更新日期:2014-07-01 00:00:00
abstract::The insulin-like growth factor (IGF) system regulates proliferation and differentiation of hematopoietic cells. IGFs exert their effects through specific receptors on growing and differentiating blood cells as they emerge from their small pool of ancestral stem cells. The IGF system is complex as both stimulating and ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190290011958
更新日期:2002-03-01 00:00:00
abstract::The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190410001663572
更新日期:2004-08-01 00:00:00
abstract::Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428194.2016.1190974
更新日期:2017-01-01 00:00:00
abstract::The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2013.772607
更新日期:2013-10-01 00:00:00
abstract::Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limite...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190410001697395
更新日期:2004-09-01 00:00:00
abstract::Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199909083378
更新日期:1999-06-01 00:00:00
abstract::A 55 year old patient with chronic lymphocytic leukemia (CLL) and long-standing excessive lymphocytosis developed a rapidly progressive neurological syndrome. Differential diagnosis focused on two rate neurological complications in this disease: direct brain infiltration by leukemic cells versus progressive multifocal...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199409049756
更新日期:1994-11-01 00:00:00
abstract::We compared bcl-2 with P-glycoprotein expression (C494 and JSB1), and both with ex vivo chemosensitivity by Differential Staining Cytotoxicity (DiSC) assay (25 cytotoxic drugs), in 76 fresh haematological specimens, including 51 chronic lymphocytic leukaemias (CLL). Strong correlations were seen between bcl-2 and Pgp ...
journal_title:Leukemia & lymphoma
pub_type: 临床试验,杂志文章
doi:10.3109/10428199609045722
更新日期:1996-12-01 00:00:00
abstract::The increased number of CD5+ B-cells in some human autoimmune diseases, the frequent commitment of CD5+ B-cells to the production of natural autoantibodies, and the apparent involvement of these cells in the pathogenesis of the autoimmune hemolytic anemia (AIHA) in certain mouse models suggests a causal relationship b...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199809092684
更新日期:1998-01-01 00:00:00
abstract::Nilotinib has shown favorable safety in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic (CML-CP) or accelerated phase (CML-AP) who failed prior imatinib, and superior efficacy over imatinib in newly diagnosed Ph+ patients with CML-CP. Reported here are the efficacy and sa...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,多中心研究
doi:10.3109/10428194.2011.627480
更新日期:2012-05-01 00:00:00
abstract::The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocytochemistry). Both methods gave reproducible and identical results when CPC were 1% or more. Using this limit, no CPC were observed in MGUS (0/11) and primary amyloid...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199409049709
更新日期:1994-08-01 00:00:00
abstract::Bronchiolitis obliterans organizing pneumonia (BOOP) presents with fever, dyspnoea, pleuritic chest pain and hypoxia. The diagnosis can be made from radiological appearances on chest radiograph and CT scan correlated with histological findings following biopsy. We present a 52-year-old gentleman undergoing treatment f...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190500144615
更新日期:2005-10-01 00:00:00
abstract::We prospectively investigated the use of [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) to kinetically monitor cell activation in six follicular lymphoma patients vaccinated with tumor lysate-pulsed autologous dendritic cells. PET revealed additional initial nodes suggestive of lymphoma, that were of...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190601094354
更新日期:2007-02-01 00:00:00
abstract::We retrospectively studied the prevalence of C1 esterase inhibitor (C1 INH) deficiency in 131 patients with various lymphomas. We determined C1 INH activity, C1 INH antigen, and C4 concentration at diagnosis and after chemotherapy. In follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and chronic lymphocy...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2015.1131273
更新日期:2016-09-01 00:00:00